ClinicalTrials.gg
RecruitingNCT06452654Updated Sep 23, 2025

Anti-viral Action Against Type 1 Diabetes Autoimmunity

A Phase 4 interventional study of Comirnaty Injectable Product and Sodium Chloride 0.9% Inj in Diabetes Mellitus, Type 1, sponsored by Technical University of Munich. Recruiting at 9 sites in 5 countries. Open to participants aged 3 Months to 4 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Technical University of Munich · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,252
Allocation
Randomized
Ages
3 Months to 4 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 30 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.

Planned enrollment
2nd of 260
2,252 · median 61
Started
2024
with 7 others
Phase 4
11 of 294
1 open now
Primary completion
2027-10
later than 15 of 29 live
Registered
269th of 294
by date
Lead sponsor
6 of 294
Technical University of Munich

Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one is the 2nd largest by planned enrollment of the 260 interventional ones that give a count, is one of 8 that started in 2024, is one of 11 in phase 4, reaches primary completion later than 15 of the 29 other live ones, and was the 269th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 3 Months to 4 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, or all of them as a file.
02

Study summary

The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or placebo from age 6 months.

The study is an investigator initiated, randomized, controlled, multicentre, multinational, primary prevention trial for children at increased risk of type 1 diabetes.

The primary objective is to determine whether vaccination of children with elevated genetic risk for type 1 diabetes against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in childhood.

Secondary objectives are:

  1. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of multiple islet autoantibodies in childhood.
  2. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of type 1 diabetes in childhood and
  3. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of celiac disease-associated transglutaminase autoantibodies in childhood.

Further exploratory objectives are described in the study protocol.

Study participants will be identified through an ongoing study screening for genetic risk of type 1 diabetes using a polygenic risk score (NCT03316261).

Eligible participants will be enrolled at age 3.00 to 4.00 months (baseline visit).

Randomization to vaccine or placebo will occur at age 6.00 to 7.00 months at visit 2. Consent will be obtained by the custodial parents prior to enrollment.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Type 1 diabetes
  • T1D
  • Diabetes mellitus
  • Autoantigen
  • Prevention
  • at risk for developing type 1 diabetes
  • Juvenile diabetes
  • Autoimmune diabetes
  • Corona
  • COVID-19
  • Viral infection
  • Viral infection surveillance
  • Immune response
  • Metabolism
04

Who can participate

Ages eligible
3 Months to 4 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages between 3.00 and 4.00 months at the time of enrollment.
  2. A high genetic risk (>10%) to develop islet autoantibodies by age 6 years as determined by a HLA DR/DQ genotype, polygenic risk score and first-degree family history of type 1 diabetes status.
  3. Written signed by the custodial parent(s).

Exclusion criteria

Exclusion Criteria:

  1. Previous to the of the vaccine.
  2. Any medical condition, concomitant disease or treatment that may interfere with the assessments or may jeopardize the participant's safe participation in the study. These include immune deficiencies, and conditions or treatments that lead to immune suppression.
  3. Likely poor compliance due to expected change in residency.
  4. Diagnosis of diabetes prior to recruitment or randomisation
  5. Current use of any other drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,252 participants (estimated)

Study arms

  • Active comparator
    Verum

    Comirnaty® 3 µg Omicron XBB.1.5 or future new variant developments replacing current Comirnaty vaccines for children Suspension for injection, for intramuscular use 1. st dose at age 6.0 to 7.0 months 2. nd dose at least 3 weeks through to 6 weeks after 1st dose 3. rd dose at least 8 weeks after 2nd dose (around age 8.5 to 11 months) Dose adjustment in case of COVID-19 infection.

    Drug: Comirnaty Injectable Product

  • Placebo comparator
    Placebo

    0.9 % Sodium Chloride Solution (saline) for intramuscular injection Dosing: three doses 1. st dose at age 6.0 to 7.0 months 2. nd dose at least 3 weeks through to 6 weeks after 1st dose 3. rd dose at least 8 weeks after 2nd dose (around age 8.5 to 11 months)

    Drug: Sodium Chloride 0.9% Inj

Interventions

  • DrugBNT162 VaccineStudies of BNT162 VaccineBNT162 Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vaccination

    Also known as: Comirnaty 3µg/dose for children for 6 month - 4 years

  • DrugSodium Chloride 0.9% Inj

    Vaccination

    Also known as: Solution for Injection

06

What researchers measure

Primary outcomes

  1. Persistent confirmed islet autoantibodies or type 1 diabetes

    The primary outcome is the elapsed time from first vaccination to the development of persistent confirmed islet autoantibodies or type 1 diabetes.

    Time frame: Through study completion, up to 6 years

Secondary outcomes

  1. Persistent confirmed multiple islet autoantibodies

    Elapsed time from first vaccination to persistent confirmed multiple islet autoantibodies;

    Time frame: Through study completion, up to 6 years

  2. Type 1 diabetes

    Elapsed time from first vaccination to type 1 diabetes.

    Time frame: Through study completion, up to 6 years

  3. Persistent confirmed transglutaminase autoantibodies

    Elapsed time from first vaccination to the development of persistent confirmed transglutaminase autoantibodies.

    Time frame: Through study completion, up to 6 years

07

Study locations

6 of 9 sites recruiting
  • Medical University of Vienna, Dept. of Pediatric and Adolescent Medicine, Waehringer Gürtel 18-20, 1090 Vienna, Austria
    Vienna, 1090, Austria
    Not yet recruiting
  • University Hospitals Leuven, Faculty of Medicine, Catholic University of Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Kristina Casteels, Prof. Dr. · Contact
  • Klinikum rechts der Isar of Technical University Munich and Institute for Diabetes Research, Helmholtz Munich
    Munich, Bavaria 80939, Germany
    Recruiting
  • AUF DER BULT, Kinder- und Jugendkrankenhaus
    Hanover, Lower Saxony 30173, Germany
    Recruiting
    • Olga Kordonouri, Prof. Dr. · Contact
  • Klinik und Poliklinik f. Kinder und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden
    Dresden, Saxony 01307, Germany
    Recruiting
    • Reinhard Berner, Prof.Dr. · Contact
  • Lund University Dep. of Clinical Sciences Malmo, Skane University Hospital SUS
    Malmö, 20213, Sweden
    Recruiting
    • Marcus Lundgren, Dr. · Contact
  • Birmingham Women's and Children's NHS Foundation Trust
    Birmingham, United Kingdom
    Not yet recruiting
    • Renuka Dias · Contact
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, United Kingdom
    Not yet recruiting
    • Loredana Marcovecchio, MD, PhD · Contact
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle, United Kingdom
    Recruiting
    • Catherine Owen, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2027, 41 months after the start.

Of 62 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 41 months is above that.

Counting every sponsor, half of 74 studies reached it within 22 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 11, 2024
StartActual
May 8, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06452654
Collaborators
Helmholtz Zentrum München, University Hospital Carl Gustav Carus, Kinderkrankenhaus auf der Bult, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Newcastle-upon-Tyne Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Birmingham Women's and Children's NHS Foundation Trust
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
May 8, 2024
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Anette-G. Ziegler, Prof. Dr.
Contact
anettegabriele.ziegler@helmholtz-munich.de
+49-89-3187 ext. 2896
Peter Achenbach, Prof. Dr.
Contact
peter.achenbach@helmholtz-munich.de
+49-89-3187 ext. 2896
Anette-G. Ziegler
principal investigator · Klinikum r.d.Isar of Technical University Munich and Institute for Diabetes Research, Helmholtz Munich, Heidemannstr.1, 80939 Munich, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion